RT Journal Article
SR Electronic
T1 Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.28.20142190
DO 10.1101/2020.06.28.20142190
A1 Stadlbauer, Daniel
A1 Tan, Jessica
A1 Jiang, Kaijun
A1 Hernandez, Matthew M.
A1 Fabre, Shelcie
A1 Amanat, Fatima
A1 Teo, Catherine
A1 Arunkumar, Guha Asthagiri
A1 McMahon, Meagan
A1 Jhang, Jeffrey
A1 Nowak, Michael D.
A1 Simon, Viviana
A1 Sordillo, Emilia Mia
A1 Bakel, Harm van
A1 Krammer, Florian
YR 2020
UL http://medrxiv.org/content/early/2020/06/29/2020.06.28.20142190.abstract
AB By conducting a retrospective, cross-sectional analysis of SARS-CoV-2 seroprevalence in a ‘sentinel group’ (enriched for SARS-CoV-2 infections) and a ‘screening group’ (representative of the general population) using >5,000 plasma samples from patients at Mount Sinai Hospital in New York City (NYC), we identified seropositive samples as early as in the week ending February 23, 2020. A stark increase in seropositivity in the sentinel group started the week ending March 22 and in the screening group in the week ending March 29. By the week ending April 19, the seroprevalence in the screening group reached 19.3%, which is well below the estimated 67% needed to achieve community immunity to SARS-CoV-2. These data potentially suggest an earlier than previously documented introduction of SARS-CoV-2 into the NYC metropolitan area.One Sentence Summary Seroprevalence of SARS-CoV-2 in cross-sectional samples from New York City rose from 0% to 19.3% from early February to mid-April.Competing Interest StatementMount Sinai has licensed serological assays to commercial entities and has filed for patent protection for serological assays.Funding StatementThis work was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (FK, for reagent generation), Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 (FK, for reagent generation), and the generous support of the JPB foundation, the Open Philanthropy Project (#2020-215611) and other philanthropic donations.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mount Sinai Hospital Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData shown in the manuscript is available from the corresponding author on reasonable request.